Table 7.
Concentration (µmol/mL) | % Cell viability∗ | |||
---|---|---|---|---|
Ursolic acid | Thujone | |||
U-937 CL# | HL-60 CL# | U-937 CL# | HL-60 CL# | |
03.13 | 73.15 ± 2.01h | 69.64 ± 0.68h | 90.17 ± 1.08h | 96.33 ± 0.78h |
06.25 | 65.18 ± 1.86g | 66.92 ± 1.31h | 85.80 ± 0.64g | 88.88 ± 0.91g |
12.50 | 59.63 ± 0.67f | 56.29 ± 0.75g | 78.38 ± 1.64f | 83.22 ± 1.10f |
25.00 | 54.69 ± 0.64e | 50.44 ± 0.79f | 71.38 ± 1.03e | 77.48 ± 1.66e |
50.00 | 44.66 ± 1.35d | 45.18 ± 0.75e | 69.67 ± 0.68e | 71.15 ± 1.23d |
100.0 | 32.74 ± 2.58c | 39.01 ± 1.17d | 64.59 ± 1.20d | 56.22 ± 0.70c |
250.0 | 27.67 ± 1.28b | 33.37 ± 1.17c | 53.85 ± 1.80c | 52.66 ± 1.52b |
500.0 | 23.08 ± 1.65a | 29.15 ± 0.55b | 42.51 ± 0.73b | 49.67 ± 0.69b |
1000 | 19.67 ± 0.98a | 23.70 ± 1.27a | 37.29 ± 1.43a | 44.66 ± 1.26a |
Control, nil mortality. ∗The values are mean of triplicates with standard deviation (mean ± S.D; n = 3). Different superscript letters (a–i) in column within treatments indicates significant differences (at p < 0.05) when subject to Tukey's multiple comparison test, CL#, cell line.